


OsmoPrep Dosing (Day before procedure)

OsmoPrep dosing for bowel preparation is a series of 2 regimens of tablets taken with a clear liquid of your choice.

Beginning at 3:00 PM

First Regimen


One dose (4 tablets with 8 oz of any clear liquid) every 15 minutes for a total of 5 doses (20 tablets)



Beginning at 9:00 P.M.

Second Regimen

One dose every 15 minutes for a total of 3 doses (12 tablets)



You must complete the entire prep to ensure the most effective cleansing.

Your body loses significant amounts of fluid during bowel preparation. In order to prevent dehydration, it is important to supplement that fluid loss with clear liquids. **Make a conscious effort to drink as much as you can before, during, and after the preparation.**

If you have any questions, please call our office at 407-560-0700.

OsmoPrep™
(sodium phosphate monobasic monohydrate, USP
and sodium phosphate dibasic anhydrous, USP) Tablets
Reliable Tolerable Tablets

www.osmoprep.com

SAFETY CONSIDERATIONS

OsmoPrep Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. Considerable caution should be advised before OsmoPrep Tablets are used in patients with severe renal insufficiency, congestive heart failure, ascites, unstable angina, gastric retention, ileus, acute obstruction or pseudo-obstruction of the bowel, severe chronic constipation, bowel perforation, acute colitis, toxic megacolon, gastric bypass or stapling surgery, or hypomotility syndrome. Use with caution in patients with impaired renal function, patients with a history of acute phosphate nephropathy, patients with a history of seizures or at higher risk of seizure, patients with higher risk of cardiac arrhythmias, known or suspected electrolyte disturbances (such as dehydration), or people taking drugs that affect electrolyte levels. Patients with electrolyte abnormalities such as hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia should have their electrolytes corrected before treatment with OsmoPrep Tablets. OsmoPrep is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients. In clinical trials, the most commonly reported adverse reactions (reporting frequency >3%) were transient and self-limited abdominal bloating, nausea, abdominal pain, and vomiting. It is recommended that patients receiving OsmoPrep Tablets be advised to adequately hydrate before, during, and after the use of OsmoPrep.

Please see full Prescribing Information for OsmoPrep.



Web site: www.salix.com 1700 Perimeter Park Drive, Morrisville, NC 27560 Tel • 866.969.SLXP (7597)
©2006 Salix Pharmaceuticals, Inc. All rights reserved. Printed in USA. OSM 06/21